Chinese Medicine: Subsidiary Obtains Registration Certificate for Injection Nicardipine Medicines.

On April 20th, Chinese pharmaceutical company announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, recently received two injection nicardipine hydrochloride "Drug Registration Certificates" issued by the State Food and Drug Administration. The drug is mainly used to treat acute heart failure and unstable angina, with 42 domestic production enterprises having obtained approval. As of the disclosure date of the announcement, the company has invested approximately 8.08 million yuan in the drug. Data shows that the sales of this drug in the top six markets in China by 2024 are expected to be around 621 million yuan, and around 218 million yuan in the first three quarters of 2025. This certification will further strengthen the company's integrated development strategy of raw materials and preparations, helping to enrich the company's product line matrix and improve product layout. Due to uncertainties such as changes in national policies and market environment, there may be situations in the future where the sales of this drug do not meet expectations.